Docetaxel enhances the cytotoxicity of anthracyclines by increasing intracellular drug accumulation

Tomohisa Egawa, Tetsuro Kubota, Akihiko Suto, Yoshihide Otani, Toshiharu Furukawa, Masahiko Watanabe, Koichiro Kumai, Masaki Kitajima

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We assessed the combined antitumor activity of docetaxel and doxorubicin (DXR) and tetrahydropyranyladriamycin (THP) using the human breast carcinoma cell lines R-27 and MDA-MB-231. Synergistic antitumor activity was observed for both combined docetaxel and DXR, and docetaxel and THP against R-27 cells when contacted simultaneously. However, only additive effects were observed against MDA-MB-231 cells. Intracellular concentrations of DXR and THP in R-27 cells were significantly increased by docetaxel pretreatment, however, this increase was not observed in MDA-MB-231 cells, which exhibited only additive sensitivity to the treatment. Thus, docetaxel increased the antitumor activity of anthracyclines by increasing their intracellular concentrations.

Original languageEnglish
Pages (from-to)777-781
Number of pages5
JournalOncology reports
Volume9
Issue number4
Publication statusPublished - 2002 Jul 1

Keywords

  • Breast cancer
  • Combination therapy
  • Docetaxel
  • Doxorubicin
  • Intracellular concentration
  • Synergism
  • Tetrahydropyranyladriamycin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Docetaxel enhances the cytotoxicity of anthracyclines by increasing intracellular drug accumulation'. Together they form a unique fingerprint.

  • Cite this

    Egawa, T., Kubota, T., Suto, A., Otani, Y., Furukawa, T., Watanabe, M., Kumai, K., & Kitajima, M. (2002). Docetaxel enhances the cytotoxicity of anthracyclines by increasing intracellular drug accumulation. Oncology reports, 9(4), 777-781.